May 19, 2014 | Israeli company Enlivex Therapeutics has raised $7 million in a convertible loan from a group of investors. Enlivex, a portfolio company of Hadasit Bio Holdings, is developing cell immunotherapy treatments for Graft versus Host Disease.
Subscribe to NoCamels weekly newsletter and get our top stories
Facebook comments